5128 results about "Clinical treatment" patented technology

A system for transferring data into and out of medical devices wherein a personal data manager (PDM) is used in a web-based network is disclosed. The PDM co-operates with a programmer to enhance remote monitoring of implanted medical devices on a chronic basis to deliver clinical therapy in real time. The PDM is handheldable and mobile and expands the reach of the programmer by storing and forwarding data from the programmer to web-based network constituting a medical environment. The PDM is also implemented to store and forward information to PCs and similar peripheral equipment. In a specialized application, the PDM is configured to exchange data with the unregulated operational/functional segments of the IMD.

The present invention relates to methods for evaluating and/or predicting the outcome of a clinical condition, such as cancer, metastasis, AIDS, autism, Alzheimer's, and/or Parkinson's disorder. The methods can also be used to monitor and track changes in a patient's DNA and/or RNA during and following a clinical treatment regime. The methods may also be used to evaluate protein and/or metabolite levels that correlate with such clinical conditions. The methods are also of use to ascertain the probability outcome for a patient's particular prognosis.

These and other objects of this invention are achieved by providing a novel method and compositions for the clinical treatment of chronic inflammatory diseases. This invention involves use of systemically administered compositions which include primary amine derivatives of benzoic acid as carbonyl trapping agents. These primary therapeutic agents act by chemically binding to and sequestering the aldehyde and/or ketone products of lipid peroxidation. Increased levels of lipid peroxidation have been repeatedly demonstrated as a part of the non-enzymatic "inflammatory cascade" process which underlies the secondary etiology of chronic inflammatory diseases. p-Aminobenzoic acid (or PABA) is an example of the primary therapeutic agent of the present invention. PABA has a small molecular weight, is water soluble, has a primary amine group that reacts with carbonyl-containing metabolites under physiological conditions and is tolerated by the body in relatively high dosages and for extended periods. The carbonyl sequestering agents are used in combination with at least one co-agent so as to produce an additional beneficial physiological effect of an anti-inflammatory nature. Such compositions are administered systemically entirely via the oral route. Co-agents of the present invention include anti-oxidants and free radical trapping compounds (e.g., alpha-tocopherol), compounds having indirect anti-oxidant activity (e.g., selenium), vitamins (e.g., pyridoxine HCl), compounds which facilitate kidney drug elimination (e.g., glycine), metabolites at risk of depletion (e.g., pantothenic acid), sulfhydryl containing chemicals (e.g., methionine), compounds which facilitate glutathione activity (e.g., N-acetylcysteine), and non-absorbable polyamine co-agents (e.g., chitosan).

A radiotherapy clinical treatment machine is described having a rotatable gantry and an imaging device with articulating robotic arms to provide variable positioning and clearance for radiation treatment applications. According to one aspect of the invention, a first and a second robotic arms are pivotally coupled to the rotatable gantry, allowing the robotic arms to maneuver independently from the rotatable gantry.

The invention discloses humanized single-domain antibodies for a novel coronavirus SARS-CoV-2 and an application of the humanized single-domain antibodies. The invention protects the single-domain antibodies described in any one of SEQ ID No.1 to SEQ ID No.5. Experimental results show that the single-domain antibodies provided by the invention have good affinity with receptor binding domain (RBD)antigens and have high neutralization activity on SARS-CoV-2 pseudovirus. The humanized single-domain antibodies have important scientific significance and application prospect for prevention and clinical treatment of the new coronavirus SARS-CoV-2 and for development of diagnostic reagents of the new coronavirus SARS-CoV-2.

The invention discloses a CAR-T transgene vector based on replication defective recombinant lentivirus. The CAR-T transgene vector comprises an original nuclear replicon pUCOri sequence, a resistance gene AmpR sequence containing ampicillin, a virus replicon SV40 Ori sequence, a lentivirus packaging cis element, ZsGreen1 green fluorescent protein, an IRES ribosome binding sequence, a human EF1 alpha promoter , a chimeric antigen receptor of second-generation CAR or third-generation CAR and a regulating element, wherein the original nuclear replicon pUCOri sequence is used for plasmid replication; the resistance gene AmpR sequence is used for massively proliferating target strains; the virus replicon SV40 Ori sequence is used for enhancing replication in eukaryocyte; the lentivirus packaging cis element is used for lentivirus packaging; the ZsGreen1 green fluorescent protein is used for expressing green fluorescent for eukaryocyte; the IRES ribosome binding sequence is used for jointly transcribing and expressing protein; the human EF1 alpha promoter is used for conducting eukaryotic transcription on antigen receptor genes; the chimeric antigen receptor is used for forming the second-generation CAR or the third-generation CAR integrating recognition, transfer and start; the regulating element is used for enhancing expression efficiency of transgenes and used after eWPRE-enhanced type woodchuck hepatitis b virus is transcribed. Besides, the invention further discloses a construction method and application of the vector. By means of the CAR-T transgene vector and the construction method and application of the vector, secretion of cell factors and an in vitro killing effect of CAR-T cells can be remarkably improved, and the clinical treatment effect is remarkable.

A method for reconstructing 3D blood vessels belongs to the field of medical detection technology for solving the accuracy problem in blood vessel reconstruction. The technical scheme is that the method can accurately reconstruct the anatomic structure of a blood vessel by combining cross section information of the blood vessel acquired by an IVUS image sequence and ultrasonic duct spatial geometrical information obtained by 3D reconstruction based on X-ray angiographic images. Compared with the reconstruction result obtained by using two single images, the method can completely and accurately reflect the actual shapes of blood vessels and possibly-existing plaques, thus providing more reliable basis for clinical treatment of coronary heart diseases and other angiopathies.

The invention discloses a stable medicinal combination which contains active ingredient riluzole and pharmaceutical auxiliary material. The medicine combination is mainly used for the clinical treatment of amyotrophic lateral sclerosis.

The invention discloses a stem cell exosome patch and its preparation method and application and belongs to the field of tissue engineering. The stem cell exosome patch comprises the following steps: stem cell is cultured and stem cell exosome is collected; a patch scaffold is prepared; and the exosome obtained is attached to the patch scaffold to prepare the stem cell exosome patch. the stem cell exosome patch obtained has natural and easily available drug sources; action site accuracy of the exosome patch can be guaranteed; effective acting time of the patch after implantation can be prolonged; and potential safety hazard can be avoided to a great extent. Through the method, the stem cell exosome patch with good biological characteristics can be obtained. The invention is a new breakthrough of establishing a biological patch in the field of tissue engineering. Meanwhile, the product also provides a feasible scheme for clinical treatment of diseases. The principle of the invention is scientific and reliable, and the technology is simple and flexible.

The invention discloses a double-layer membranous tissue repair material and a preparation method thereof, wherein, a cell-free membranous biological derivative material is used as a surface layer, and a fibroblast is compounded in the interior of a biological support material to form a substrate, and then the surface layer and the substrate are combined in a chimeric way to form the double-layer membranous tissue repair material; a compact surface layer structure can effectively reduce the loss of water, electrolytes and protein from surface of wound, avoid the invading and the reproduction of bacteria to the impaired surface of wound as well as prevent the infection of the surface of wound, thus being beneficial to epitheliosis and epithelial growth; the substrate can directly repair the surface of wound, promote the ingrowth of cells around the surface of wound and the angiogenesis, induce the differentiation from stem cells to skin cells and quicken wound healing; compared with the existing products, the tissue repair material has the advantages of being capable of promoting the regeneration of skin, improving the elasticity, the flexibility and the mechanical abrasion resistance of skin after the surface of wound is healed, reducing hyperplasia of scar tissues, controlling the contracture, having excellent biocompatibility, increasing the success rate of transplant and improving the quality of healing; the invention has wide material resources and simple production method; the double-layer membranous tissue repair material prepared is applicable to the clinical treatment of skin defect caused by inflammation, ulcer, thermal burns, iatrogenicity and the like.

The invention relates to a method for preparing human umbilical cord mesenchymal stem cells, which comprises the steps of collection, transportation, handover, separation, freezing, recovering, primary culture and subculture of umbilical cords. The method has simple process, ensures low production cost, good freezing effect, little cell damage, low toxic side effect and no harm to human body and reduces the residual of the freezing protection liquid in the recovered cells of tissue blocks; and the prepared mesenchymal stem cells can be applied to the clinical treatment of various diseases.

The invention belongs to the field of allogenic mesenchymal stem cells, and particularly relates to a preparation method of allogenic mesenchymal stem cells by CRISPR (clustered regularly interspaced short palindromic repeats) technique editing and IGF (insulin-like growth factor) optimization and application of the allogenic mesenchymal stem cells in treating myocardial infarction. The preparation method comprises the following steps: carrying out separation by density gradient centrifugation to obtain allogenic single karyocytes, and carrying out adherent culture to obtain mesenchymal stem cells; designing a mesenchymal stem cell surface antigen B2M-gRNA and an inflammatory factor TNF-alpha-gRNA; establishing recombinant slow virus particles, and transfecting the mesenchymal stem cells; optimizing the mesenchymal stem cells by using IGF-1; and preparing drugs for treating myocardial infarctions by using the modified and optimized mesenchymal stem cells. The CRISPR/Cas9 technique is utilized to remove the antigens capable of causing immunological rejection and the inflammatory factors capable of causing inflammatory reaction on the mesenchymal stem cell surface, and the IGF-1 is utilized to enhance the apoptosis resistance of the mesenchymal stem cells and promote the homing of the mesenchymal stem cells, thereby providing a new technical scheme for preparing drugs for treating cardiovascular diseases in clinic. The prepared allogenic mesenchymal stem cells can not cause immunological rejection after cell transplantation.

The invention discloses a new traditional Chinese medicine composition for treating insomnia and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following raw Chinese medicinal herbal materials: cinnabar, nacre mother of pearl, cortex albiziae, semen boitae, tuber fleeceflower stem, polygala root, amber, fossil fragments, spina date seed, glossy ganoderma, shell of abalone, oyster, gastrodia elata, root of straight ladybell, ophiopogon japonicus, lucid asparagus, fruit of Chinese wolfberry, fushen, motherwort, Chinese angelica, radix paeoniae alba, cortex lycii radicis, agilawood, root of three-nerved spicebush, rhizoma cyperi and the like. The traditional Chinese medicine composition can be prepared into any one common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can remarkably improve symptoms of insomnia, difficulty falling asleep, easy awakening, difficulty falling asleep after awakening, alternation of falling asleep and awakening, difficulty falling asleep all through the night, doldrums, slow response, fatigue, even vexation and the like, and has the advantages of accurate clinical treatment effect, remarkable treatment effect, low cost, basically no toxic or side effects, and the like.

The invention relates to a biodegradable stent composite material and a preparation method thereof. The degradable material has a multi-gradient composite structure, and comprises a matrix made of a medical metal or an alloy thereof, a chemical coupling layer attached to the surface of the matrix, a high polymer transition layer attached to the surface of the chemical coupling layer and a degradable high polymer functional layer fixed on the surface of the high polymer transition layer. The stent composite material has high mechanical property, degradation property and biocompatibility, also can absorb and carry needed therapeutic medicaments, and meets the requirement on clinical treatment. The degradable composite material can be used as stent materials of esophagi, biliary ducts, intestinal tracts, urethrae, tracheae and other non-vessel lumens and blood vessels, and also can be used for manufacturing artificial bones, bone nails, bone connectors, bone sutures, anchors for suture, intervertebral discs, hemostatic clamps, hemostatic forceps, hemostatic plates, hemostatic screws, tissue adhesives, sealants and other medical devices and products.

Provided are novel nanostructures comprising hollow nanospheres and nanotubes for use as chemical sensors and molecular specific photothermal coupling agents. The nanostructures can be used in laser-induced phototherapy for treatment of cancer and other disorders. The nanostructures can also be used as a sensor that detects molecules. The nanostructures are of particular use in the fields of clinical diagnosis, clinical therapy, clinical treatment, and clinical evaluation of various diseases and disorders, manufacture of compositions for use in the treatment of various diseases and disorders, for use in molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof. The hollow gold nanospheres have a unique combination of spherical shape, small size, and strong, tunable, and narrow surface plasmon resonance absorption covering the entire visible to near IR region.

The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen replacement and/or other clinical therapeutic and/or diagnostic areas.

The invention discloses a new traditional Chinese medicine composition for treating cerebral thrombosis and cerebral infarction and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following Chinese medicinal herbs such as dutchmanspipe root, fruit of immature citron, dried orange peel, pangolin scales, ground beeltle, ligusticum wallichii, cassia twig, angelica sinensis, radix paeoniae alba, root of red-rooted salvia, agilawood, rhizoma cyperi, rhizoma corydalis, radix curcumae, pseudo-ginseng, common burreed rhizome, curcuma zedoary, red flower, peach kernel, rhizoma gastrodiae, uncaria rhynchophylla, white muscardine silkworm, scorpio, styrax asiatic styrax and rhizoma acori graminei. The traditional Chinese medicine composition can be prepared into any one common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can remarkably improve the symptoms of aphasia from apoplexy, facial paralysis, numb hands and feet, blindness, dizziness and faint, hypertension, blood viscosity increase, insufficiency of cerebral blood supply and the like, and has accurate clinical treatment effect, remarkable treatment effect and rapid effect. The traditional Chinese medicine composition has the advantages of low cost, basically no toxic or side effects and the like.

The invention discloses a novel Chinese medicinal composition for treating antiaditis and a preparation method thereof. The Chinese medicinal composition mainly comprises the following raw material medicaments: blackberrykiky rhizome, immature bitter orange, Chinese eaglewood, szechuan lovage rhizome, tangerine peel, costustoot, radish seed, szechwan chinaberry fruit, longstamen onion bulb, honey suckle flower, philippine violet herb, mongolian dandelion herb, weeping forsythiae capsule, figwort root, fresh rehmannia, lightyellow sophora root, baical skullcap root, chrysanthemum, bupleurum, kudzuvine root, mint, great burdock achene, gypsum, anemarrhena asphodeloides bunge, common lophatherum herb, mongolian snakegourd root, gentian, heartleaf houttuynia herb, dahurian patrinia herb and the like. The Chinese medicinal composition can be prepared into any one common orally-taken preparation by a conventional Chinese medicinal preparation method. The Chinese medicinal composition can remarkably improve the symptoms: antiaditis, antiadoncus, inflamed and purulent pharynx, ardor and pain, bitter mouth and dry pharynx, dry congh, cough and the like, and has extract clinical treatment effect, remarkable treatment effect and quick response. The Chinese medicinal composition also has the advantages of low cost, basically no toxic or side effect and the like.

The invention discloses a method for controlling the quality of ginkgo leaves and an extract thereof. After the screening of a great quantity of experiments, the method adopts ultra-high performance liquid chromatography for detection; and the method can be used for detecting three types of components including flavone, terpene lactones and phenolic acid, twenty-four active compounds in total, in the ginkgo leaves and the extract of the ginkgo leaves. The results of the experiments prove that the method is high in detection sensitivity and good in stability, and can be used for objectively, comprehensively and accurately evaluating the quality of ginkgo leaf medicines, the extract of the ginkgo leaves and ginkgo leaf preparations, thus having important significance on controlling the quality and guaranteeing the clinical treatment effect.

The present invention pertains to an ultrasound therapy system and more specifically, to a high-intensity focused ultrasound (HIFU) therapy apparatus guided by image registration and fusion method. The therapy system of the present invention comprises a central control means; an acoustic energy applicator; a mechanical driving and locating means of said acoustic energy applicator; a real-time B-mode ultrasound image guiding device. Further the therapy system of the present invention comprises an immobilization means for body position. By the help of this immobilization means for body position, real-time B-mode ultrasound images can be registered with diagnosis images, and then on the basis of registration, said B-mode ultrasound images are fused with said diagnosis images for guiding said therapy. Comparing to the existed technical solutions in this field, the present invention has effectively solved the difficult problems in high-intensity focused ultrasound therapy and particularly for tumor treatment with a low cost. And it provides a very practical technical solution, which can be easily applied to clinical treatment of tumors.